News from the CHMP and CMDh – October 2013
30.10.2013
The Co-ordination Group for the Mutual Recognition and Decentralised Procedure for Human Medicines (CMDh) has adopted the PRAC recommendations about restrictions of use of hydrxyethyl-starch containing solutions (HES) and restrictions of use of short acting beta agonists in obstetric indications.
The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) confirmed its previous recommendations about the restriction of use of dihydroergotoxin and metoclopramide and recommended restriction of use of intravenous forms of nicardipine.
More information is accessible under the following link.
more